Mohamad Allaf
Has grant
Department Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL)
Open Date: 2022-02-04
Close Date: 2028-07-31
Grant: Close
Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection
Open Date: 2020-09-11
Close Date: 2025-06-30
Articles (8)
Self-reported Black (B) individuals remain underrepresented in molecular studies of clear-cell renal cell carcinoma (ccRCC) relative to White (W) individuals. We performed whole-exome and transcriptome sequencing on paired tumor and normal samples from 59 matched B and W patients undergoing nephrectomy for localized ccRCC, comparing molecular differences by estimated genetic similarity to African (AFR) and European (EUR) 1000 Genomes groups. We validated our findings with a propensity-matched subset of The Cancer Genome Atlas, yielding a final cohort of 254 patients (79 AFR and 175 EUR) with similar baseline clinical variables. Significant differences emerged in VHL mutation frequency (AFR: 23.4%, EUR: 57.5%; FDR = 0.0029) and chromosome 3p deletions (AFR: 59.2%, EUR: 82.6%; FDR = 0.086). Transcriptomic analyses identified 34 genes associated with genetic similarity, and gene set enrichment revealed inflammatory (IFN-γ/IFN-α, allograft rejection), proliferative (E2F targets, G2–M checkpoint), and metabolic (bile acid, fatty acid, glycolysis, MTORC1, peroxisome) pathway enrichment in EUR. We also observed differences in ccRCC molecular subtype distribution, with “Proliferative” and “Angio/Stromal” subtypes being more common in AFR (P = 0.018). Importantly, differential subtype membership explained most group-level differences. These results link EUR and AFR genetic similarity to distinct ccRCC molecular subtypes, underscoring the importance of molecular classifiers in disease stratification and the need to include diverse populations in molecular studies to improve our understanding and treatment of ccRCC. Significance: Our study shows that AFR genetic similarity correlates with distinct ccRCC molecular subtypes. Further research is needed to disentangle environmental and genetic influences. Identifying these differences underscores the critical importance of including racially and ethnically diverse populations in cancer research to ensure more equitable and sustainable outcomes worldwide for all patients.
Year:
2025
Differential expression analysis and hallmark gene set enrichment of AFR vs. EUR groups. A, Wald statistic of DEGs comparing AFR T vs. EUR T ( x -axis) and AFR N vs. EUR N ( y -axis). Colored points depict significant genes with an FDR-adjusted P n = 73), blue representing genetic similarity–associated genes in normal comparisons ( n = 74), and red representing genes that are significant in both comparisons ( n = 1). B, Volcano plot depicting DEGs in AFR vs. EUR in the TCGA cohort ( n = 8,739 DEGs, 4,952 AFR-associated, 3,787 EUR-associated). DEGs in A and B are defined as having an FDR-adjusted P value 2 fold change >0.5. Labeled points are significantly altered in both JHU and TCGA comparisons ( n = 34). C, Heatmap of hallmark gene set enrichment results performed on the DEGs produced in A and B . Plotted values are directional [−log 10 (adj. P )], where orange/red depicts enrichment in the AFR group and blue depicts enrichment in the EUR group.
Year:
2025
ccRCC driver mutations by AFR and EUR groups, race, and RCC clinical risk factors. A, OncoPrint of ccRCC driver mutations split by AFR and EUR groups. B, Frequency of VHL mutations in patients by HTN history, eGFR group, and self-reported race. Group-wise P values were calculated using Fisher’s exact test. Mut, mutant; SNV, single nucleotide variant; Wt, wild-type.
Year:
2025
AFR and EUR groups are associated with distinct ccRCC molecular subtypes. A, Distribution of IMm151 molecular subtypes among AFR and EUR groups. B, GSVA of differentially enriched hallmark gene sets by IMm151 subtype (top) and further subsetted by genetic similarity (bottom). Box plots depict the median, upper quartile, and lower quartile GSVA scores. P values were calculated by the Kruskal–Wallis test. Statistical significance is as follows: *, P P P P
Year:
2025
Self-reported Black (B) individuals remain underrepresented in molecular studies of clear-cell renal cell carcinoma (ccRCC) relative to White (W) individuals. We performed whole-exome and transcriptome sequencing on paired tumor and normal samples from 59 matched B and W patients undergoing nephrectomy for localized ccRCC, comparing molecular differences by estimated genetic similarity to African (AFR) and European (EUR) 1000 Genomes groups. We validated our findings with a propensity-matched subset of The Cancer Genome Atlas, yielding a final cohort of 254 patients (79 AFR and 175 EUR) with similar baseline clinical variables. Significant differences emerged in VHL mutation frequency (AFR: 23.4%, EUR: 57.5%; FDR = 0.0029) and chromosome 3p deletions (AFR: 59.2%, EUR: 82.6%; FDR = 0.086). Transcriptomic analyses identified 34 genes associated with genetic similarity, and gene set enrichment revealed inflammatory (IFN-γ/IFN-α, allograft rejection), proliferative (E2F targets, G 2 –M checkpoint), and metabolic (bile acid, fatty acid, glycolysis, MTORC1, peroxisome) pathway enrichment in EUR. We also observed differences in ccRCC molecular subtype distribution, with “Proliferative” and “Angio/Stromal” subtypes being more common in AFR ( P = 0.018). Importantly, differential subtype membership explained most group-level differences. These results link EUR and AFR genetic similarity to distinct ccRCC molecular subtypes, underscoring the importance of molecular classifiers in disease stratification and the need to include diverse populations in molecular studies to improve our understanding and treatment of ccRCC. Significance: Our study shows that AFR genetic similarity correlates with distinct ccRCC molecular subtypes. Further research is needed to disentangle environmental and genetic influences. Identifying these differences underscores the critical importance of including racially and ethnically diverse populations in cancer research to ensure more equitable and sustainable outcomes worldwide for all patients.
Year:
2025
AFR and EUR groups are associated with a distinct tumor microenvironment composition. A, Heatmap of xCell results performed on the pooled analytic cohort ( n = 78 AFR and n = 175 EUR). Values are row-scaled xCell enrichment scores for lymphoid, myeloid, and stromal cell types ( n = 38 cell types). B, Box plots depict xCell enrichment scores for differentially enriched cell types. Box plot borders depict the median, upper quartile, and lower quartile. P values were determined by the Kruskal–Wallis test with multiple hypothesis correction. Statistical significance is as follows: *, P P P P
Year:
2025
AFR and EUR groups drive somatic alterations in ccRCC independent of AFR genetic similarity percentage. A, Density plot of AFR genetic similarity by self-reported race demonstrating a bimodal distribution. Frequency of somatic mutations ( B ) and cytoband gains/losses ( C ). P values were determined by Fisher’s exact test and corrected for FDR. D, Logistic regression of AFR percentage among B individuals ( n = 69) vs. VHL mutation status. P values were calculated by logistic regression and adjusted for multiple hypothesis testing by Benjamini–Hochberg. n.s., not significant.
Year:
2025
VHL mutation status is associated with both molecular subtype and genetic similarity. A, OncoPrint of ccRCC driver mutations split by IMm151 molecular subtype. P values were calculated using Fisher’s exact test. B, Frequency of VHL mutations in patients by IMm151 molecular subtype and AFR/EUR grouping. P values were calculated using Fisher’s exact test. Mut, mutant; SNV, single nucleotide variant; wt, wild-type.
Year:
2025
Collaborators (4)
Ridwan Alam
Assistant Professor
Northwestern University
Alison Klein
Professor
-
Srinivasan Yegnasubramanian
-
Elana Fertig
Assistant Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Make your next move.
Prepare your application
Review drafts before you send them.